{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:09:22Z","timestamp":1786990162601,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.htct.2022.06.009","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T19:42:18Z","timestamp":1659987738000},"page":"253-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: A longitudinal study with a pre-infusion protocol"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-8146","authenticated-orcid":false,"given":"Thales Silva","family":"Antunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7400-7406","authenticated-orcid":false,"given":"Karina Mescouto","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0515-6971","authenticated-orcid":false,"given":"Cl\u00e1udia Fran\u00e7a Cavalcante","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-7551","authenticated-orcid":false,"given":"Fab\u00edola Scancetti","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3S","key":"10.1016\/j.htct.2022.06.009_bib0001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.htct.2022.06.009_bib0002","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaci.2008.08.012","article-title":"Immunoglobulin therapy: methods of delivery","volume":"122","author":"Ballow","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.htct.2022.06.009_bib0003","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.htct.2022.06.009_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/s1679-45082017ae3844","article-title":"II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies","volume":"15","author":"Goudouris","year":"2017","journal-title":"Einstein"},{"issue":"4","key":"10.1016\/j.htct.2022.06.009_bib0005","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.iac.2008.07.001","article-title":"Immunoglobulin replacement therapy in children","volume":"28","author":"Garcia-Lloret","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.htct.2022.06.009_bib0006","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.htct.2022.06.009_bib0007","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.iac.2015.07.006","article-title":"Immunoglobulin Replacement Therapy for Primary Immunodeficiency","volume":"35","author":"Sriaroon","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.htct.2022.06.009_bib0008","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"Quinti","year":"2011","journal-title":"J Clin Immunol"},{"issue":"7","key":"10.1016\/j.htct.2022.06.009_bib0009","first-page":"514","article-title":"Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency","volume":"21","author":"Baris","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"10.1016\/j.htct.2022.06.009_bib0010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","article-title":"Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment","volume":"36","author":"Routes","year":"2016","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.htct.2022.06.009_bib0011","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.aller.2012.09.006","article-title":"Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America","volume":"42","author":"Condino-Neto","year":"2014","journal-title":"Allergol Immunopathol"},{"issue":"3","key":"10.1016\/j.htct.2022.06.009_bib0012","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"issue":"2","key":"10.1016\/j.htct.2022.06.009_bib0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.htct.2022.06.009_bib0014","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.aller.2020.05.008","article-title":"Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement","volume":"48","author":"Ibis","year":"2020","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.htct.2022.06.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108826","article-title":"Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin","volume":"230","author":"Esmaeilzadeh","year":"2021","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.htct.2022.06.009_bib0016","first-page":"139","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Khavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"10.1016\/j.htct.2022.06.009_bib0017","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaip.2013.09.012","article-title":"Adverse effects of IgG therapy","volume":"1","author":"Berger","year":"2013","journal-title":"J Allergy Clin Immunol Pract. de"},{"issue":"2","key":"10.1016\/j.htct.2022.06.009_bib0018","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","volume":"23","author":"Bichuetti-Silva","year":"2014","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.htct.2022.06.009_bib0019","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.htct.2022.06.009_bib0020","first-page":"11","article-title":"Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience","volume":"49","author":"Kaba","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.htct.2022.06.009_bib0021","first-page":"1","article-title":"Report of a WHO scientific group","volume":"109","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.htct.2022.06.009_bib0022","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/clim.1999.4799","article-title":"Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)","volume":"93","author":"Conley","year":"1999","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.htct.2022.06.009_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.htct.2022.06.009_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.htct.2022.06.009_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","article-title":"Increased risk of adverse events when changing intravenous immunoglobulin preparations","volume":"136","author":"Ameratunga","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.htct.2022.06.009_bib0026","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2340\/00015555-0900","article-title":"Not all intravenous immunoglobulin preparations are equally well tolerated","volume":"90","author":"Feldmeyer","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.htct.2022.06.009_bib0027","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5415\/apallergy.2013.3.4.249","article-title":"Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study","volume":"3","author":"Palabrica","year":"2013","journal-title":"Asia Pac Allergy"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:36:31Z","timestamp":1762868191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137922000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2531137922000979"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2022.06.009","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: A longitudinal study with a pre-infusion protocol","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2022.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}